Regulating the Sale of Pharmaceutical Drugs in Cameroon: An Insight into the Institutional Mechanism
Keywords:
Pharmaceutical, drugs (medicines), regulationAbstract
In this era of globalisation, scientific development and the growing recognition and awareness of the direct link between drugs and human health, governments, scholars and consumers (patients) etc, are increasingly getting concerned about the quality and safety of the drugs sold and consumed whether as prevention or as cure to an ailment. These drugs sold both in the formal and informal sectors are sometimes wanting and dangerous to the health of the consumers (patients). It is for this reason that drug quality control aims at ensuring that pharmaceutical drugs that are sold for consumption does not only conform to national requirements so as to ensure the health of consumers but also to meet the safety and quality specifications of the World Health Organisation’s (WHO) and consequently international standards. Such considerable standards or obligations are placed by regulatory authorities on drugs manufactured within the country as well as those imported. Effective regulation of this activity is difficult as evident in the recent outbreak of the COVID-19 pandemic, where even licensed pharmaceutical companies were discovered to have been supplying and distributing fake chloroquine to wholesalers and consumers. This paper therefore seeks to investigate into the regulatory authorities that have been put in place to ensure effective control of pharmaceutical drugs in Cameroon by looking at their various roles. It is assumed that the institutions put in place can better guarantee effective control if the required resources are made available. While adopting the doctrinal and empirical methods of data collection it is discovered that informal pharmaceutical drugs dealing in Cameroon is also promoted by corrupt activities making effective regulation challenging.
References
1. Nikola T. (2018). Medical Law and Health Law —Is It the Same? Acta Medica Medianae, Vol.57(2), p. 34.
2. Medical law covers an area of regulations relating to the medical operations, the industry operators, the procedures involved in the medical operations, characterist ics of medical experts performing medical operations as well as the relations that occurred while performing medical activities.
3. Health law regulates a wide area of activities, not only medical activities, but also the procedures that are being implemented, the need and necessity of the procedure, professionals who carry out the procedure.
4. Lowe RF, Montagu D. (2009). Legislation, Regulation, and Consolidation in the Retail Pharmacy Sector in Low Income Countries. Southern Medical Review. Vol 2; Issue 2, p. 35.
5. Nidhi BA, Manoj K. (2018). Pharmaceutical Regulations in India . Pharmaceutical Medicine and Translational Clinical Research, at https://www.sciencedirect.com/topics/medicine-and- dentistry/pharmaceuticals-regulation (accessed on the 30th day of April 2020).
6. Cameroon being a member, inclusive.
7. At https://www.who.int/medicines/areas/quality_safety/quality_assurance/WHO-Guidelines- Import-Procedures-pharmaceutical-productsQAS18-773_09.05.2018.pdf?ua=1 (accessed on the 5th day of May 2020)
8. At https://import-export.societegenerale.fr/en/country/cameroon/regulations-customs (accessed on the 1st day of May 2020).
9. There exist 40 approved distribution pharmacies in Cameroon spread in all the ten regions.
10. See Decree No. 98/405/PM of 22nd October 1998 setting the terms of approval and marketing of pharmaceutical products in Cameroon and also Order No. 2515/A/MINSANTE/SG/DPML/DAJC relating to the conditions for granting approvals to wholesale pharmaceutical companies in Cameroon.
11. See Lettre Circulaire No. D36 -26 LC/MINSANTE/SG/DPML du 17 Juillet 2019 Relative aux irrégularités constatées dans le secteur de la promotion/visite médicale au Cameroun and Circular Letter No. D36 -44 CL/MOH/SG/DPML of 2nd October 2019 Concerning to the irregularities observed in promotion/sales representatives’ sector in Cameroon.
12. Nebot GA, Schiavetti B, Meessen B, et al . (2017). Quality Assurance of Medicines Su pplied to Low-income and Middle -income Countries: Poor Products in Shiny Boxes? BMJ Global Health 2:e000172. doi:10.1136/bmjgh-2016-000172, p. 1
13. Almuzaini T, Choonara I, Sammons H. (2013) . Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open 3:e002923, p. 1
14. Nebot GA, Schiavetti B, Meessen B, et al. (2017), Loc.cit, p. 2
15. Margareth N.S., et al (2017) . Medicines Regulation in Africa: Current State and Opportunities . Pharm Med, 31: DOI 10.1007/s40290-017-0210-x, p. 383.
16. Eghan K, Daniel G. (2011). Assessment of the Pharmaceutical Management System in Cameroon. Submitted to the US Agency for International Development by the Strengthening Pharmaceutical Systems (SPS) Program. Arlington, VA: Management Sciences for Health, p. 5.
17. Its head office is found in Yaounde, political capital of Cameroon, directly behind the Ministry of Finance and facing the National Museum.
18. The present Minister of Public Health is Dr Malachie MANAOUDA.
19. This department of the Ministry of Public Health is d etached from the main head office in Yaounde and is located at Mballa II opposite the Jamot Hospital.
20. The Health Analytical Profile 2016, Cameroon, coordinated by Andre Mama Fouda, Minister of Public Health, African Health Observatory, World Health Organization, p. 58.
21. It was established by Decree No. 2002/209 of 29th August 2002 on the organisation of the Ministry of Public Health.
22. See Section 8 of Decree No. 2013/093 of 03 April 2013 to Organise the Ministry of Public Health.
23. See Article 81(1) of Decree N ° 2013/093 of 03 April 2013 Organising the Ministry of Public Health.
24. Information gotten from time spent at the DPML
25. Eghan K. and Daniel G., (2011), Loc.cit, p. 6.
26. See Article 82(2) of Decree N° 2013/093 of 03 April 2013 to Organise the Ministry of Public Health
27. See Article 82(1), Ibid.
28. Ibid, Article 83(1) states its missions.
29. Ibid, Article 83(2).
30. Ibid, Article 84(1).
31. Ibid, Article 84(2).
32. Ibid, Article 85(1)
33. Ibid, Article 85(2)
34. Ibid, Article 86(1)
35. Ibid, Article 86(2)
36. Ibid, Article 87(1)
37. Ibid, Article 87(2)
38. Ibid, Article 88(1)
39. Ibid, Article 88(2)
40. Ibid, Article 89(1)
41. Ibid, Article 89(2)
42. See Article 8(1) of Decree N° 2013/093 of 03 April 2013 to Organise the Ministry of Public Health.
43. Eghan K. and Daniel G., (2011), Op.cit, p. 6.
44. Margareth N.S., et al (2017), Op,cit, p.384
45. Information on the main functions of the NPRA gotten during time spent at the Ministry of Public Health.
46. See Article 3 of the Order No. 102/CAB/PM of 18th November 2019 on the creation of a National Multi-sectorial Commission for the Fight against Fake Medicine and Traffic in Illicit Pharmaceutical Products in Cameroon.
47. The Coronavirus (COVID -19) that was first discovered in Wuhan, China on the 19th day of December 2019.
48. Cameroon registering close to 2000 infected persons and about 100 deaths by the 1st day of May 2020.
49. Article 2, supra.
50. Article 4, supra.
51. Article 7, supra.
52. Article 6(2), supra.
53. Article 6(1), supra.
54. At www.minsante.gov.cm (accessed on the 11th day of October 2019)
55. See Article 17 of Decree No. 98/405 / PM of 22nd October 1998 setting the terms of approval and marketing of pharmaceutical products in Cameroon.
56. Decision No. 314/CAB/MINSANTE of 16th November 1999 on the nomination of members of the National Medicine Commission.
57. See Article 19, of Decree No. 98/405 / PM of 22nd October 1998 setting the terms of approval and marketing of pharmaceutical products in Cameroon.
58. See Article 20, Ibid.
59. Eghan K. and Daniel G., (2011), Loc.cit, p. 6.
60. Article 18, supra.
61. Article 22, supra.
62. Article 25, supra.
63. See Article 20, supra.
64. Decree No. 2005/252 of 30th June 2005 creating the National Supply Centre of Essential Drugs and Consumables.
65. Decree No. 2018/501 of 20th September 2018 reorganising the National Supply Centre of Essential Drugs and Consumables.
66. http://www.ministryofminescm.com/quality-control/ (accessed on the 11th day of D ecember 2020)
67. https://cameroonpostline.com/quality-control-of-imported-goods-begins-august-31/%E2%80%8B (accessed on the 11th day of December 2020)
68. Decree No. 2016/0003/PM of 13th January 2016 creating the National Consumers Council
69. Epang S -N. (2018) . Consumer Protection: National Council to Set up Surveillance System . Cameroon-report, at https://cameroon-report.com/societe/consumer-protection-national-council- to-set-up-surveillance-system/ (accessed on the 11th day of December 2020).
70. See Section 25(1) of the 2011 Framework Law on Consumer Protection in Cameroon.
71. Neba SK. (2018), Consumer Protection: A Prime Ministerial order creates National Consumers Council at http://www.crtv.cm/2018/03/consumer-protection-ministerial-order-creates-national- consumption-council/ (accessed on the 11th day of December 2020).
72. See Section 25(2) of the 2011 Framework Law on Consumer Protection in Cameroon.
73. http://www.who.int/en/ (accessed on the 3rd day of March 2020).
74. Van Boxtel CJ, et al. Drug Benefits and Risks: International Textbook of Clinical Pharmacology, revised 2nd edition, IOS Press and Uppsala Monitoring Centre, 2008, p. 74.
75. http://www. who.int/medicines/publications/newsletter/en/index. Html (accessed on the 4th day of March 2020).
76. Van Boxtel C.J., et al. Op.cit, p. 75.
77. http://www.who.int/druginformation/ (accessed on the 4th day of March 2020).
78. Van Boxtel CJ, et al. Loc.cit, p. 75
79. World Health Organi zation, (2011), Marketing Authorization of Pharmaceutical Products with Special Reference to Multisource (Generic) Products, a manual for National Medicines Regulatory Authorities (NMRAs), Geneva Switzerland.
80. Vandenborre T, Import of quality medicines into developing countries: The impact of the complex regulated pharmaceutical environment on the supply chain of Médecins Sans Frontières (MSF) Masters thesis su bmitted in International Trade and Global Marketing, The Global Business School, Ninove, 2014, p. 16 at https://www.researchgate.net/publication/289670943 (accessed on the 1st day of May 2020).
81. Hill (S) and Kent (J), (2004), Emerging Challenges and Opportu nities in Drug Registration and Regulation in Developing Countries, DFID Health Systems Resource Centre, p. 38.
82. Ibid, p. 17.
83. Hill S, Kent J. (2004), Op.cit, p. 39.
84. Mir IJ, et al . (2017). Medicines Management in Hospitals: A Supply Chain Perspective . Systematic Reviews in Pharmacy, Vol. 8, Issue 1, p. 83.
85. World Health Organization. (2017). Access to medicines: making market forces serve the poor, p. 16 at www.who.int/publications/10-year-review/en/ (accessed on the 18th of May 2020).
86. WHO Medical Product Alert No. 3/2019, where an investigation established that a new falsified version of the drug ICLUSIG 45mg (30 Tabletten) was circulating the world market, issu ed through a press release of the Minister of Public Health.
87. WHO Medical Product Alert N°4/2020 on falsified chloroquine products circulating in the WHO region of Africa in the midst of the COVID-19 pandemic.
88. www.who.int/medicines/regulation/tsn/en/ (accessed on the 18th day of May 2020)
89. World Health Organi zation, (2019), Access to medicines and vaccines, Seventy -Second World Health Assembly, p. 12.
90. See Law No. 95-53 of 19th December 1990 relating to freedom of association which provides the rules of establishing associations in Cameroon.
91. Created by Decree No. 2010/371 on the 14th of December 2010 as the second Anglo-Saxon university in Cameroon after the University of Buea
92. The Association was created in 2017 and duly registered and acknowledged following the 1990 Law on Freedom of Association by Prefecterial Order No. 034/ARDA/F.34/ALPAS of 4th June 2020.
93. Ratanawijitrasin S , Wondemagegnehu E. Effective Drug Regulation: A multicountry study, Geneva: World Health Organization, 4th edition, 2002, p. 12.
94. Butt ZA, et a l. (2005). Quality of pharmacies in Pakistan: a cross -sectional survey. International
95. Adikwu MU, (1996). Sales practices of patent medicine sellers in Nigeria . Health Policy Plan, Vol. 11(2), p. 205.
